CZ20011550A3 - Opticky aktivní derivát pyridyl-4H-1,2,4-oxadiazinu, jeho použití při léčbě vaskulárních onemocnění a farmaceutické kompozice ho obsahující - Google Patents

Opticky aktivní derivát pyridyl-4H-1,2,4-oxadiazinu, jeho použití při léčbě vaskulárních onemocnění a farmaceutické kompozice ho obsahující

Info

Publication number
CZ20011550A3
CZ20011550A3 CZ20011550A CZ20011550A CZ20011550A3 CZ 20011550 A3 CZ20011550 A3 CZ 20011550A3 CZ 20011550 A CZ20011550 A CZ 20011550A CZ 20011550 A CZ20011550 A CZ 20011550A CZ 20011550 A3 CZ20011550 A3 CZ 20011550A3
Authority
CZ
Czechia
Prior art keywords
oxadiazine
pyridyl
comprised
pharmaceutical compositions
optically active
Prior art date
Application number
CZ20011550A
Other languages
English (en)
Other versions
CZ300764B6 (cs
Inventor
Andrea Jednákovits
László Ürögdi
László Dénes
István Kurucz
Ede Márványos
Mihály Barabás
Erno Bácsy
Zsuzsanna Korom
Zoltán Nagy
László Ürge
Jeno Szilbereky
Károly Acsai
Péter Krajcsi
Zita Csákai
Magdolna Török
Original Assignee
Biorex Kutató És Fejlesztö Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutató És Fejlesztö Rt. filed Critical Biorex Kutató És Fejlesztö Rt.
Publication of CZ20011550A3 publication Critical patent/CZ20011550A3/cs
Publication of CZ300764B6 publication Critical patent/CZ300764B6/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
CZ20011550A 1998-12-14 1999-12-07 Opticky aktivní derivát pyridyl-4H-1,2,4-oxadiazinu, jeho použití pri lécbe vaskulárních onemocnení a farmaceutické kompozice ho obsahující CZ300764B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient

Publications (2)

Publication Number Publication Date
CZ20011550A3 true CZ20011550A3 (cs) 2001-08-15
CZ300764B6 CZ300764B6 (cs) 2009-08-05

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20011550A CZ300764B6 (cs) 1998-12-14 1999-12-07 Opticky aktivní derivát pyridyl-4H-1,2,4-oxadiazinu, jeho použití pri lécbe vaskulárních onemocnení a farmaceutické kompozice ho obsahující

Country Status (27)

Country Link
US (1) US6384029B1 (cs)
EP (1) EP1147105B1 (cs)
JP (2) JP2002532498A (cs)
KR (1) KR100661774B1 (cs)
AT (1) ATE266027T1 (cs)
AU (1) AU765336B2 (cs)
BG (1) BG65179B1 (cs)
BR (1) BR9913982A (cs)
CA (1) CA2340734C (cs)
CZ (1) CZ300764B6 (cs)
DE (1) DE69917074T2 (cs)
DK (1) DK1147105T3 (cs)
EE (1) EE04551B1 (cs)
ES (1) ES2219091T3 (cs)
HR (1) HRP20010133B1 (cs)
HU (1) HU226617B1 (cs)
IL (1) IL141515A (cs)
NO (1) NO317649B1 (cs)
PL (1) PL196584B1 (cs)
PT (1) PT1147105E (cs)
RS (1) RS50129B (cs)
RU (1) RU2222538C2 (cs)
SI (1) SI1147105T1 (cs)
SK (1) SK285582B6 (cs)
UA (1) UA70340C2 (cs)
WO (1) WO2000035914A1 (cs)
ZA (1) ZA200101182B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533795A (en) 2002-01-11 2006-03-31 Biorex Kutato Fejlesztoe Kft Carboxamidine derivatives and their use in the treatment of vascular diseases
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
CA2728363C (en) 2008-06-26 2019-02-19 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
CN102215842A (zh) 2008-11-18 2011-10-12 参天制药株式会社 含有吡啶-3-甲醛o-(哌啶-1-基-丙基)-肟衍生物作为有效成分的脉络膜视网膜变性疾病的治疗剂
AU2011335545A1 (en) 2010-11-30 2013-06-13 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
PT3193840T (pt) 2014-09-15 2021-08-10 Orphazyme Aps Formulação de arimoclomol
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
KR102254140B1 (ko) 2016-04-29 2021-05-24 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
AU2018274176A1 (en) 2017-05-24 2020-01-16 Zevra Denmark A/S Heat shock protein inducers and frontotemporal disorders
JP2021525864A (ja) 2018-05-28 2021-09-27 オーファザイム エー/エス 疾患のバイオマーカーとしてのPBMCサンプル中のHsp70タンパク質レベル
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
AU7324196A (en) * 1995-11-03 1997-05-22 Global Trading Uk Limited Apparatus for dispensing and filling bags at a checkout counter of a supermarket
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
DE69917074D1 (de) 2004-06-09
PL346767A1 (en) 2002-02-25
AU1790600A (en) 2000-07-03
KR100661774B1 (ko) 2006-12-28
ZA200101182B (en) 2002-02-12
AU765336B2 (en) 2003-09-18
JP2011201916A (ja) 2011-10-13
SI1147105T1 (en) 2004-08-31
CA2340734A1 (en) 2000-06-22
ES2219091T3 (es) 2004-11-16
HRP20010133A2 (en) 2002-02-28
YU25001A (sh) 2004-07-15
WO2000035914A1 (en) 2000-06-22
NO20012310L (no) 2001-05-10
IL141515A0 (en) 2002-03-10
DK1147105T3 (da) 2004-06-01
HUP9802897A2 (hu) 2000-11-28
BG105342A (en) 2001-12-29
RU2222538C2 (ru) 2004-01-27
CA2340734C (en) 2008-10-21
JP2002532498A (ja) 2002-10-02
KR20010073129A (ko) 2001-07-31
ATE266027T1 (de) 2004-05-15
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
SK285582B6 (sk) 2007-04-05
EE04551B1 (et) 2005-10-17
RS50129B (sr) 2009-03-25
EE200100188A (et) 2002-08-15
BG65179B1 (bg) 2007-05-31
BR9913982A (pt) 2001-06-12
HRP20010133B1 (en) 2005-02-28
JP5620340B2 (ja) 2014-11-05
EP1147105A1 (en) 2001-10-24
SK2342001A3 (en) 2001-08-06
UA70340C2 (en) 2004-10-15
EP1147105B1 (en) 2004-05-06
NO317649B1 (no) 2004-11-29
PL196584B1 (pl) 2008-01-31
IL141515A (en) 2005-09-25
HU226617B1 (en) 2009-04-28
DE69917074T2 (de) 2005-05-12
NO20012310D0 (no) 2001-05-10
PT1147105E (pt) 2004-07-30
US6384029B1 (en) 2002-05-07
CZ300764B6 (cs) 2009-08-05

Similar Documents

Publication Publication Date Title
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
GB0005251D0 (en) Therapeutic compounds
ZA919317B (en) Novel hydroxamic acid and N-hydroxyurea derivatives and their use.
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
IE790756L (en) Cerebral therapeutic agent
GEP20033025B (en) 4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
CZ20011550A3 (cs) Opticky aktivní derivát pyridyl-4H-1,2,4-oxadiazinu, jeho použití při léčbě vaskulárních onemocnění a farmaceutické kompozice ho obsahující
IL109534A0 (en) Pour-on formulations containing polymeric material, glycols and glycerides and a process for their preparation
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
ATE110714T1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
DK1492539T3 (da) Statin-terapi til forögelse af kognitiv funktion
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
FR2673105B1 (fr) Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections.
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
HUP9802896A3 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
DE69511247T2 (de) Therapeutische benzonitrile
UA30143C2 (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
FR2804867B1 (fr) Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
GEP20002141B (en) Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20111207